SCHEMBL6298090

SCHEMBL6298090

c1ccc(C2=NN(c3ccccn3)C(c3ccccc3)C2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESD P10768 1/20 0.61
MEN1 O00255 8/20 0.56
KMT2A Q03164 8/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
MAOB P27338 4/20 0.55
MAOA P21397 3/20 0.55
KDM4E B2RXH2 3/20 0.53
ALDH1A1 P00352 3/20 0.53
GAA P10253 3/20 0.53
ATM Q13315 3/20 0.53
GLA P06280 2/20 0.53
MAPT P10636 2/20 0.53
HTT P42858 1/20 0.53
GFER P55789 1/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
CFTR P13569 1/20 0.53
HPGD P15428 1/20 0.53
GOPC Q9HD26 1/20 0.53
PRKCZ Q05513 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27997398 0.91 ESD (0.61) ESDMEN1KMT2AL3MBTL1MAOB
SCHEMBL7586677 0.90 MEN1 (0.53) ESDMEN1KMT2AL3MBTL1MAOB
SCHEMBL6292699 0.82 ESD (0.75) ESDMEN1KMT2AMAOBMAOA
SCHEMBL23052404 0.81 MEN1 (0.73) MEN1KMT2AL3MBTL1MAOBMAOA
SCHEMBL395608 0.81 MEN1 (0.73) MEN1KMT2AL3MBTL1MAOBMAOA
SCHEMBL22796281 0.81 ESD (0.53) ESDKMT2AL3MBTL1MAOBMAOA
SCHEMBL10855110 0.81 ESD (0.53) ESDMEN1KMT2AL3MBTL1MAOB
SCHEMBL27902102 0.78 NR3C2 (0.60) MEN1KMT2AL3MBTL1MAOBMAOA
SCHEMBL10361833 0.78 MEN1 (0.69) MEN1KMT2AL3MBTL1MAOBMAOA
SCHEMBL14338087 0.78 MEN1 (0.69) MEN1KMT2AL3MBTL1MAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030083351-A1 Medicinal uses of dihydropyrazoles THE PROCTER & GAMBLE COMPANY 2003-05-01 US claimed
US-20050090532-A1 Medicinal uses of dihydropyrazoles THE PROCTER & GAMBLE COMPANY 2005-04-28 US disclosed
US-6878729-B2 Medicinal uses of dihydropyrazoles THE PROCTER & GAMBLE COMPANY (US) 2005-04-12 US disclosed
US-20030083351-A1 Medicinal uses of dihydropyrazoles THE PROCTER & GAMBLE COMPANY 2003-05-01 US disclosed
WO-2002089799-A2 USE OF DIHYDROPYRAZOLES TO INCREASE ERYTHROPOIETIN AND VASCULARI ZATION THE PROCTER & GAMBLE COMPANY (US) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090532-A1 Medicinal uses of dihydropyrazoles EPOR, VEGFA, FLT4 ESD 2222/4885MEN1 3356/4885KMT2A 4588/4885
US-20030083351-A1 Medicinal uses of dihydropyrazoles EPOR, VEGFA, TEK ESD 2918/4885MEN1 3141/4885KMT2A 4671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.